Lundbeck
6 Parkway North
Deerfield
Illinois
60015
United States
Tel: 224-507-1000 and (866) 337-6996
Website: http://www.lundbeckus.com/
About Lundbeck
At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. Headquartered in Copenhagen with a U.S. home office in Deerfield, Ill., Lundbeck is the only global biopharmaceutical company focused solely on brain diseases. Our legacy in neuroscience goes back seven decades and we have a long heritage of innovation. Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for psychiatric and neurological disorders. Today, we remain uncompromisingly committed to improving the quality of life for people impacted by brain disorders. Lundbeck is unique from other biopharmaceutical companies in that we are 70 percent owned by a research-focused foundation. We have a deep and productive pipeline, and we continue to bring forward symptomatic therapies to help people live better lives, while simultaneously pursuing disease-modifying treatments.
Offices in
LaJolla, CA - Lundbeck La Jolla Research Center, Inc.
Bothell, WA - Lundbeck Seattle BioPharmaceuticals, Inc
Stock Exchange: Copenhagen
Stock Symbol: LUN.CO
What Makes Lundbeck a Top Workplace?”
189 articles with Lundbeck
-
The American Academy of Neurology Virtual Annual Meeting 2021 is ongoing from April 17 through 22, with literally hundreds of presentations. Here’s a peek at just some of them.
-
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
-
Clinical Catch-Up: August 3-7
8/10/2020
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. -
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
-
AHS Posters for Lundbeck’s VYEPTI™ (eptinezumab-jjmr) in Migraine Prevention Evaluated Early Onset of Action and Reduction in Medication-Overuse Headache
6/13/2020
Post-hoc closed testing analysis suggests onset of a migraine preventive effect with intravenous VYEPTI as early as day 1 following the initial dose
-
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
-
AllianceRx Walgreens Prime one of only two specialty pharmacies to distribute Vyepti™, the first and only intravenous preventive treatment for migraine
5/19/2020
New medicine one of several limited distribution drugs available through specialty pharmacy
-
BioSpace Global Roundup, April 9
4/9/2020
Biopharma companies from across the globe provide updates to their business operations and pipelines. -
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds
3/25/2020
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds The PROMISE 2 study met its primary endpoint, with VYEPTI demonstrating statistically significant reductions in mean monthly migraine days (MMD) after the first dose over months 1-3 The preventive effects of VYEPTI were demonstrated as early as day 1 post-infusion and sustained thro
-
FDA Approves Lundbeck’s VYEPTI™ (eptinezumab-jjmr) – The First and Only Intravenous Preventive Treatment for Migraine
2/22/2020
In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), VYEPTI met its primary endpoint: decrease in mean monthly migraine days (MMD) over months 1-3.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
Lundbeck selects Discngine’s 3decision® platform to leverage complex protein-ligand 3D structure data in the discovery of new treatments for brain diseases
9/4/2019
Discngine announces that Lundbeck has selected its proprietary 3decision® collaborative platform to manage the pharma company’s structural knowledge related to protein and ligand 3D structures.
-
P1vital announces launch of the Reward Task Optimisation Consortium - RTOC
7/22/2019
Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.
-
Lundbeck Tops Corporate Reputation Rankings for Fourth Consecutive Year
5/31/2019
Annual survey finds Lundbeck US is first among leading pharmaceutical companies in the eyes of patient groups.
-
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
-
Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research
1/7/2019
Collaboration sets out to identify potential treatment candidates for disorders of the central nervous system including depression, psychosis, seizure and neurodegenerative disorders.
-
Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care Partners
9/24/2018
Symptoms of nOH may affect approximately one in five people with Parkinson’s Disease
-
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
-
Catalyst Pharmaceuticals Expands Commercial Leadership Team
8/6/2018
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
-
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
5/23/2018
Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.